These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 15958090)
1. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Ramsaransing GS; Heersema DJ; De Keyser J Eur J Neurol; 2005 Jul; 12(7):514-8. PubMed ID: 15958090 [TBL] [Abstract][Full Text] [Related]
2. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Liu B; Shen Y; Xiao K; Tang Y; Cen L; Wei J Neurol Res; 2012 Mar; 34(2):163-71. PubMed ID: 22333889 [TBL] [Abstract][Full Text] [Related]
3. [The absence of a relation between apolipoprotein E genotypes and the severity of multiple sclerosis in Mexican patients]. Corona T; Guerrero-Camacho JL; Alonso-Vilatela ME; Flores-Rivera Jde J Rev Neurol; 2010 Jan 1-15; 50(1):19-22. PubMed ID: 20073019 [TBL] [Abstract][Full Text] [Related]
4. Demyelinating lesions in the cervical cord in multiple sclerosis 10 years after onset of the disease. Correlation between MRI parameters and clinical course. Bonek R; Orlicka K; Maciejek Z Neurol Neurochir Pol; 2007; 41(3):229-33. PubMed ID: 17629816 [TBL] [Abstract][Full Text] [Related]
5. Apo E in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis. Pinholt M; Frederiksen JL; Andersen PS; Christiansen M Mult Scler; 2005 Oct; 11(5):511-5. PubMed ID: 16193886 [TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736 [TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422 [TBL] [Abstract][Full Text] [Related]
9. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Zakrzewska-Pniewska B; Styczynska M; Podlecka A; Samocka R; Peplonska B; Barcikowska M; Kwiecinski H Mult Scler; 2004 Jun; 10(3):266-71. PubMed ID: 15222689 [TBL] [Abstract][Full Text] [Related]
11. Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis. Simental-Mendía E; Simental-Mendía LE; Guerrero-Romero F Neurol Sci; 2017 Sep; 38(9):1665-1669. PubMed ID: 28660563 [TBL] [Abstract][Full Text] [Related]
12. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. Booth DR; Arthur AT; Teutsch SM; Bye C; Rubio J; Armati PJ; Pollard JD; Heard RN; Stewart GJ; J Mol Med (Berl); 2005 Oct; 83(10):822-30. PubMed ID: 16075257 [TBL] [Abstract][Full Text] [Related]
13. [Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis]. Guerrero AL; Bueno V; Hernández MT; Martín-Serradilla JI; Carrasco E; Cuadrado I Neurologia; 2003 Apr; 18(3):146-8. PubMed ID: 12677480 [TBL] [Abstract][Full Text] [Related]
14. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Enzinger C; Ropele S; Strasser-Fuchs S; Kapeller P; Schmidt H; Poltrum B; Schmidt R; Hartung HP; Fazekas F Arch Neurol; 2003 Jan; 60(1):65-70. PubMed ID: 12533090 [TBL] [Abstract][Full Text] [Related]
15. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. Malhotra S; Fissolo N; Tintoré M; Wing AC; Castilló J; Vidal-Jordana A; Montalban X; Comabella M J Neuroinflammation; 2015 Mar; 12():48. PubMed ID: 25879961 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. Savettieri G; Andreoli V; Bonavita S; Cittadella R; Caltagirone C; Fazio MC; Girlanda P; Le Pira F; Liguori M; Logroscino G; Lugaresi A; Nocentini U; Reggio A; Salemi G; Serra P; Tedeschi G; Toma L; Trojano M; Valentino P; Quattrone A J Neurol; 2003 Sep; 250(9):1094-8. PubMed ID: 14504972 [TBL] [Abstract][Full Text] [Related]
17. No effect of APOE and PVRL2 on the clinical outcome of multiple sclerosis. Ramagopalan SV; Deluca GC; Morrison KM; Herrera BM; Dyment DA; Orton S; Bihoreau MT; Degenhardt A; Pugliatti M; Sadovnick AD; Sotgiu S; Ebers GC J Neuroimmunol; 2007 May; 186(1-2):156-60. PubMed ID: 17376543 [TBL] [Abstract][Full Text] [Related]
18. Association of apolipoprotein E genotypes with prognosis in multiple sclerosis. Tamam Y; Tasdemir N; Yalman M; Tamam B Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1122-30. PubMed ID: 22165672 [TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. van der Walt A; Stankovich J; Bahlo M; Taylor BV; van der Mei IA; Foote SJ; Kilpatrick TJ; Rubio JP; Butzkueven H Neurology; 2009 Sep; 73(13):1018-25. PubMed ID: 19786693 [TBL] [Abstract][Full Text] [Related]
20. Uric acid: a potential biomarker of multiple sclerosis and of its disability. Moccia M; Lanzillo R; Palladino R; Russo C; Carotenuto A; Massarelli M; Vacca G; Vacchiano V; Nardone A; Triassi M; Morra VB Clin Chem Lab Med; 2015 Apr; 53(5):753-9. PubMed ID: 25241733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]